IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER

被引:8
|
作者
Aguloglu, Nursin [1 ]
Aksu, Aysegul [1 ]
Akyol, Murat [1 ]
Katgi, Nuran [1 ]
Doksoz, Tugce Ciftci [1 ]
机构
[1] Bahcesehir Cam & Sakura Hastanesi, Istanbul, Turkey
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2022年 / 61卷 / 06期
关键词
18F-FDG-PET; CT; Lung cancer; Textural analysis; EGFR; ALK; IMAGING PHENOTYPES; SOMATIC MUTATIONS; ADENOCARCINOMA;
D O I
10.1055/a-1868-4918
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Identification of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutation types is of great importance before treatment with tyrosine kinase inhibitors (TKIs). Radiomics is a new strategy for noninvasively predicting the genetic status of cancer. We aimed to evaluate the predictive power of 18F-FDG PET/CT-based radiomic features for mutational status before treatment in non-small cell lung cancer (NSCLC) and to develop a predictive model based on radiomic features. Methods Images of patients who underwent 18F-FDG PET/CT for initial staging with the diagnosis of NSCLC between January 2015 and July 2020 were evaluated using LIFEx software. The region of interest (ROI) of the primary tumor was established and volumetric and textural features were obtained. Clinical data and radiomic data were evaluated with machine learning (ML) algorithms to create a model. Results For EGFR mutation prediction, the most successful machine learning algorithm obtained with GLZLM_GLNU and clinical data was Naive Bayes (AUC: 0.751, MCC: 0.347, acc: 71.4%). For ALK rearrangement prediction, the most successful machine learning algorithm obtained with GLCM_correlation, GLZLM_LZHGE and clinical data was evaluated as Naive Bayes (AUC: 0.682, MCC: 0.221, acc: 77.4%). Conclusions In our study, we created prediction models based on radiomic analysis of 18F-FDG PET/CT images. Tissue analysis with ML algorithms are non-invasive methods for predicting ALK rearrangement and EGFR mutation status in NSCLC, which may be useful for targeted therapy selection in a clinical setting.
引用
收藏
页码:433 / 439
页数:7
相关论文
共 50 条
  • [1] Performance of 18F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer
    Zhang, Min
    Bao, Yiming
    Rui, Weiwei
    Shangguan, Chengfang
    Liu, Jiajun
    Xu, Jianwei
    Lin, Xiaozhu
    Zhang, Miao
    Huang, Xinyun
    Zhou, Yilei
    Qu, Qian
    Meng, Hongping
    Qian, Dahong
    Li, Biao
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [2] Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer
    Zhang, Jianyuan
    Zhao, Xinming
    Zhao, Yan
    Zhang, Jingmian
    Zhang, Zhaoqi
    Wang, Jianfang
    Wang, Yingchen
    Dai, Meng
    Han, Jingya
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (05) : 1137 - 1146
  • [3] Value of 18F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
    Lv, Zhilei
    Fan, Jinshuo
    Xu, Juanjuan
    Wu, Feng
    Huang, Qi
    Guo, Mengfei
    Liao, Tingting
    Liu, Shuqing
    Lan, Xiaoli
    Liao, Shanshan
    Geng, Wei
    Jin, Yang
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (05) : 735 - 750
  • [4] Relationship between 18F-FDG PET/CT radiometabolic markers and EGFR mutation, positive ALK Expression in patients with non-small cell lung cancer
    Gayaf, Mine
    Anar, Ceyda
    Aksel, Nimet
    Erbaycu, Ahmet Emin
    Koporal, Hakan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2021, 69 (04): : 437 - 448
  • [5] Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients
    Wang, Yubo
    Han, Rui
    Wang, Qiushi
    Zheng, Jie
    Lin, Caiyu
    Lu, Conghua
    Li, Li
    Chen, Hengyi
    Jin, Rongbing
    He, Yong
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 347 - 356
  • [6] Impact of 18F-FDG PET/CT in the Treatment of Patients With Non-Small Cell Lung Cancer
    Taus, Alvaro
    Aguilo, Rafael
    Curull, Victor
    Suarez-Pinera, Marina
    Rodriguez-Fuster, Alberto
    Rodriguez de Dios, Nuria
    Pijuan, Lara
    Zuccarino, Flavio
    Vollmer, Ivan
    Sanchez-Font, Albert
    Belda-Sanchis, Jose
    Arriola, Edurne
    ARCHIVOS DE BRONCONEUMOLOGIA, 2014, 50 (03): : 99 - 104
  • [7] The added value of 18F-FDG PET/CT in staging non-small cell lung cancer
    Sheha, Aliaa S.
    Elia, Remon Zaher
    Ghoneim, Nada Mohammed Farid Hassan
    EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2019, 50 (01):
  • [8] 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer
    Guan, Jian
    Xiao, Nan J.
    Chen, Min
    Zhou, Wen L.
    Zhang, Yao W.
    Wang, Shuang
    Dai, Yong M.
    Li, Lu
    Zhang, Yue
    Li, Qin Y.
    Li, Xiang Z.
    Yang, Mi
    Wu, Hu B.
    Chen, Long H.
    Liu, Lai Y.
    MEDICINE, 2016, 95 (30)
  • [9] 18F-FDG PET/CT SUVmaxand serum CEA levels as predictors for EGFR mutation state in Chinese patients with non-small cell lung cancer
    Gao, Xi-Can
    Wei, Chun-Hua
    Zhang, Rui-Guang
    Cai, Qian
    He, Yong
    Tong, Fan
    Dong, Ji-Hua
    Wu, Gang
    Dong, Xiao-Rong
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [10] Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer
    Kirchner, Julian
    Sawicki, Lino M.
    Nensa, Felix
    Schaarschmidt, Benedikt M.
    Reis, Henning
    Ingenwerth, Marc
    Bogner, Simon
    Aigner, Clemens
    Buchbender, Christian
    Umutlu, Lale
    Antoch, Gerald
    Herrmann, Ken
    Heusch, Philipp
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (02) : 437 - 445